# Bendamustine and Bevacizumab for Advanced Cancers

> **NCT01152203** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 59 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT01152203
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2015-11-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01152203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01152203, "Bendamustine and Bevacizumab for Advanced Cancers". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01152203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*